Moreover, the fact that Lgr5− differentiated tumour cells must re-express Lgr5 in order to repopulate the CSC pool, following its depletion during treatment [297], or to colonize the distant site [302] holds promise for ongoing efforts to develop LGR5 antibody-drug conjugates [293,355,389]. The gene discussed is LGR5; the disease is neoplasm.